• BIOMARCER-2
    Share

Trial Status

In Development

Cancer Type

Colorectal Cancer

If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.

Protocol Title

BIOMARCER-2 – Biomarker informed optimal management of advanced RAS wild type colorectal cancer in right sided disease

Purpose of the Study

Choosing the optimal therapy for patients with metastatic colorectal cancer is challenging. We now have access to a simple pathology test for a biomarker than can tell us who might benefit most from Epidermal Growth Factor Receptor inhibitors (EGFRi), which are commonly used in advanced colorectal cancer. The study aims to demonstrate progression free survival benefit of EGFRi for right sided RAS/BRAF wild-type, metastatic colorectal cancer.

 

Contact Email

TBC

DETAILED INFORMATION AVAILABLE

More detailed information to come.

Principal Investigator

Dr Shehara Mendis

Funding

2021 Innovation Grant

Trial Status

In Development

Cancer Type

Colorectal Cancer

If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.